These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 11153722)

  • 1. Should an angiotensin-converting enzyme inhibitor be standard therapy for patients with atherosclerotic disease?
    O'Keefe JH; Wetzel M; Moe RR; Bronsnahan K; Lavie CJ
    J Am Coll Cardiol; 2001 Jan; 37(1):1-8. PubMed ID: 11153722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin-converting enzyme inhibition in patients with coronary artery disease and preserved left ventricular function Ischemia Management with Accupril post-bypass graft via inhibition of angiotensin-converting enzyme (IMAGINE) compared with the other major trials in coronary artery disease.
    van Gilst WH; Warnica JW; Baillot R; Johnstone D; Calciu CD; Block P; Myers MG; Chocron S; Rouleau JL;
    Am Heart J; 2006 Jun; 151(6):1240-6. PubMed ID: 16781228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvement of cardiac function by angiotensin converting enzyme inhibition. Sites of action.
    Dietz R; Waas W; Süsselbeck T; Willenbrock R; Osterziel KJ
    Circulation; 1993 May; 87(5 Suppl):IV108-16. PubMed ID: 8485825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors.
    Linz W; Wiemer G; Gohlke P; Unger T; Schölkens BA
    Pharmacol Rev; 1995 Mar; 47(1):25-49. PubMed ID: 7784479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardioprotective effect of angiotensin-converting enzyme inhibitors in patients with coronary artery disease.
    Ferrari R; Ceconi C; Curello S; Pepi P; Mazzoletti A; Visioli O
    Cardiovasc Drugs Ther; 1996 Nov; 10 Suppl 2():639-47. PubMed ID: 9115958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacotherapy of arteriosclerosis and its complications. Effect of ACE inhibitors and HMG-CoA-reductase inhibitors].
    Tschudi MR; Noll G; Lüscher TP
    Schweiz Med Wochenschr; 1997 Apr; 127(15):636-49. PubMed ID: 9198890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Congestive heart failure: what should be the initial therapy and why?
    Chatterjee K
    Am J Cardiovasc Drugs; 2002; 2(1):1-6. PubMed ID: 14727993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolution of angiotensin-converting enzyme inhibition in hypertension, heart failure, and vascular protection.
    Parmley WW
    Am J Med; 1998 Jul; 105(1A):27S-31S. PubMed ID: 9707265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential indications for angiotensin-converting enzyme inhibitors in atherosclerotic vascular disease.
    Halkin A; Keren G
    Am J Med; 2002 Feb; 112(2):126-34. PubMed ID: 11835951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiotensin converting enzyme inhibition and coronary artery disease.
    Pepine CJ
    J Hypertens Suppl; 1994 Jul; 12(4):S65-71. PubMed ID: 7965277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin antagonism in coronary artery disease: results after coronary revascularisation.
    Ribichini F; Ferrero V; Rognoni A; Vacca G; Vassanelli C
    Drugs; 2005; 65(8):1073-96. PubMed ID: 15907144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The potential role of angiotensin-converting enzyme inhibition in peripheral arterial disease.
    Hirsch AT; Duprez D
    Vasc Med; 2003 Nov; 8(4):273-8. PubMed ID: 15125489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiotensin-converting enzyme inhibitors and coronary artery disease.
    Sayer JW; Timmis AD
    Cardiovasc Drugs Ther; 1996 Nov; 10 Suppl 2():631-7. PubMed ID: 9115957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Should angiotensin-converting enzyme-inhibitors be used to improve outcome in patients with coronary artery disease and 'preserved' left ventricular function?
    Fox K; Ferrari R; Yusuf S; Borer JS
    Eur Heart J; 2006 Sep; 27(18):2154-7. PubMed ID: 16905555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Towards 2001: will ACE inhibitors have a role in atherosclerosis treatment?
    Sharpe N
    Int J Clin Pract Suppl; 1998 May; 94():26-31. PubMed ID: 9926442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulating atherosclerosis through inhibition or blockade of angiotensin.
    Rosenson RS
    Clin Cardiol; 2003 Jul; 26(7):305-11. PubMed ID: 12862295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system.
    Scheen AJ
    Drugs; 2004; 64(22):2537-65. PubMed ID: 15516153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Debate: angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers--a gap in evidence-based medicine.
    Ball SG; White WB
    Am J Cardiol; 2003 May; 91(10A):15G-21G. PubMed ID: 12781904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiatherosclerotic effects of ACE inhibitors: where are we now?
    Lonn E
    Am J Cardiovasc Drugs; 2001; 1(5):315-20. PubMed ID: 14728013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.